Pluvicto (lutetium Lu 177 vipivotide tetraxetan) - Novartis
Quantitative Systems Pharmacology Modeling of Targeted Radiotherapies to Predict Absorbed Dose, Inform NextGeneration Design, and Improve Therapeutic Index (EANM 2026) - Sep 29, 2026 - Abstract #EP-0199; "The model was calibrated to published clinical biodistribution data for 177Luvipivotide tetraxetan, with physiological parameters obtained from the literature... QSP modeling provides a mechanistically grounded framework to integrate ligand and isotope properties, target biology, and clinical data for targeted radiotherapies. By capturing both dynamic biodistribution and cumulative radiation exposure, this approach supports absorbed dose prediction, compound optimization, target feasibility assessment, and rational dose selection. As TRTs continue to advance, QSP models represent a valuable tool to guide design decisions for improved therapeutic index and for the development of next-generation candidates." 
https://www.sciencedirect.com/science/article/pii/S3051291326002855?via%3Dihub
 
S. Minucci; B. Koirala; B. Lang; J. Nosbisch; A. Manon; D. Imbs; J. Grant
 
Sep 29, 2026
 
Prev Next